Reduced CXCL1/GRO chemokine plasma levels are a possible biomarker of elderly depression.


Journal

Journal of affective disorders
ISSN: 1573-2517
Titre abrégé: J Affect Disord
Pays: Netherlands
ID NLM: 7906073

Informations de publication

Date de publication:
15 Apr 2019
Historique:
received: 08 11 2018
revised: 11 02 2019
accepted: 12 02 2019
pubmed: 4 3 2019
medline: 14 6 2019
entrez: 4 3 2019
Statut: ppublish

Résumé

Depression is the single largest contributor to non-fatal health loss worldwide. A role of inflammation in major depressive disorder (MDD) was suggested, and we sought to determine if cytokine levels predict the severity of depressive symptomatology or distinguish MDD patients from healthy controls (HCs). The severity of depressive symptoms and cognitive impairment were assessed by the Korean version of the Geriatric Depression Scale (GDS-K) and Mini-Mental State Examination (MMSE-KC) in 152 elderly subjects (76 with MDD). Plasma levels of 28 cytokines were measured and analysed as continuous predictors or dichotomized using the median value. The association between individual cytokines, MDD risk and depressive symptoms severity was investigated using multiple logistic and linear regressions that included the relevant covariates. A Cytokine Weighted Score (CWS) was calculated by weighting cytokines according to previously reported effect sizes on MDD risk. Sensitivity analyses were performed excluding subjects with significant cognitive impairment. CXCL10/IP-10 levels were higher in subjects with MDD vs. HCs while the opposite was observed for CXCL1/GRO. Only the second association survived after adjusting for possible confounders and excluding subjects with severe cognitive impairment. Using dichotomized cytokine levels, CXCL1/GRO and TNF-α were negatively associated with MDD. The CWS was also negatively associated with MDD. Cytokine levels did not predict the severity of depressive symptoms. Our cross-sectional approach was not able to longitudinally evaluate any temporal fluctuations in the considered cytokine levels. This study found significantly lower CXCL1/GRO chemokine plasma levels in elderly subjects with MDD compared to HCs.

Sections du résumé

BACKGROUND BACKGROUND
Depression is the single largest contributor to non-fatal health loss worldwide. A role of inflammation in major depressive disorder (MDD) was suggested, and we sought to determine if cytokine levels predict the severity of depressive symptomatology or distinguish MDD patients from healthy controls (HCs).
METHODS METHODS
The severity of depressive symptoms and cognitive impairment were assessed by the Korean version of the Geriatric Depression Scale (GDS-K) and Mini-Mental State Examination (MMSE-KC) in 152 elderly subjects (76 with MDD). Plasma levels of 28 cytokines were measured and analysed as continuous predictors or dichotomized using the median value. The association between individual cytokines, MDD risk and depressive symptoms severity was investigated using multiple logistic and linear regressions that included the relevant covariates. A Cytokine Weighted Score (CWS) was calculated by weighting cytokines according to previously reported effect sizes on MDD risk. Sensitivity analyses were performed excluding subjects with significant cognitive impairment.
RESULTS RESULTS
CXCL10/IP-10 levels were higher in subjects with MDD vs. HCs while the opposite was observed for CXCL1/GRO. Only the second association survived after adjusting for possible confounders and excluding subjects with severe cognitive impairment. Using dichotomized cytokine levels, CXCL1/GRO and TNF-α were negatively associated with MDD. The CWS was also negatively associated with MDD. Cytokine levels did not predict the severity of depressive symptoms.
LIMITATIONS CONCLUSIONS
Our cross-sectional approach was not able to longitudinally evaluate any temporal fluctuations in the considered cytokine levels.
CONCLUSIONS CONCLUSIONS
This study found significantly lower CXCL1/GRO chemokine plasma levels in elderly subjects with MDD compared to HCs.

Identifiants

pubmed: 30826620
pii: S0165-0327(18)32856-8
doi: 10.1016/j.jad.2019.02.042
pii:
doi:

Substances chimiques

Biomarkers 0
CXCL1 protein, human 0
Chemokine CXCL1 0
Cytokines 0
Tumor Necrosis Factor-alpha 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

410-417

Informations de copyright

Copyright © 2019 Elsevier B.V. All rights reserved.

Auteurs

Giuseppe Fanelli (G)

Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy.

Francesco Benedetti (F)

Psychiatry and Clinical Psychobiology Unit, Division of Neuroscience, San Raffaele Scientific Institute, Milan, Italy.

Sheng-Min Wang (SM)

Department of Psychiatry, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.

Soo-Jung Lee (SJ)

Department of Psychiatry, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.

Tae-Youn Jun (TY)

Department of Psychiatry, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.

Prakash S Masand (PS)

Global Medical Education, New York, NY, USA.

Ashwin A Patkar (AA)

Department of Psychiatry and Behavioural Sciences, Duke University Medical Center, Durham, NC, USA.

Changsu Han (C)

Department of Psychiatry, College of Medicine, Korea University, Seoul, Republic of Korea.

Alessandro Serretti (A)

Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy.

Chi-Un Pae (CU)

Department of Psychiatry, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea; Department of Psychiatry and Behavioural Sciences, Duke University Medical Center, Durham, NC, USA; Cell Death Disease Research Center, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea. Electronic address: pae@catholic.ac.kr.

Chiara Fabbri (C)

Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH